Skip to main content

Personalized CAR T Cell Therapy™

Learn More Today

You are here

In the Media

Lentigen Technology Inc., a Miltenyi Biotec Company, Acquires University of Maryland, Baltimore CAR-T Cell Start-Up, Living Pharma, Inc.

Lentigen Technology Inc., a leading provider of GMP lentiviral vectors, will further advance Living Pharma’s personalized chimeric antigen receptor (CAR) T-cell therapies targeting various cancers.

» Read more

Living Pharma Adds Noted Oncologist to its Advisory Board

Living Pharma, Inc. announced today that it has added Aaron P. Rapoport, MD, to its advisory board.

» Read more

Living Pharma Adds Venture Capital Executive to its Advisory Board

Living Pharma, Inc. announced today that it has added Isai Peimer, PhD, to its advisory board.

» Read more

Living Pharma Signs Exclusive License Agreement with UMB for a Novel Universal CAR T Cell Platform Technology

Living Pharma, Inc. announced today that it has entered into an exclusive license agreement with the University of Maryland, Baltimore (UMB) to develop Anti-Tag Chimeric Antigen Receptor (AT-CAR™) engineered T cell therapy.

» Read more